Skip to main content
Sickle Cell DiseaseDrugRadiationProcedurePhase 2

What this study is

The study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant (HSCT).

The primary objective of the study is to determine the engraftment at Day +60 following HLA-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents and low-dose total body irradiation (TBI) for conditioning and post-transplant cyclophosphamide in patients with sickle cell disease.

What's being tested

  • ATG

    Intervention · DRUG

    0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7

  • fludarabine

    Intervention · DRUG

    30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2

  • cyclophosphamide

    Intervention · DRUG

    14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4

  • Total body irradiation

    Intervention · RADIATION

    3 Gy on day -1

  • Stem cell infusion

    Intervention · PROCEDURE

    Stem cell product infused according to BMT unit policy on day 0.

  • Sirolimus

    Intervention · DRUG

    loading dose of 15 mg followed by 5 mg per day on day +5

  • mycophenolate mofetil

    Intervention · DRUG

    1 g every 8 h (until day 35) will be started on day 5

Study details

Official title
A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Sponsor
University of Illinois at Chicago
Conditions
Sickle Cell Disease
Enrolling
50 people
Starts
2017-03-20
Est. completion
2026-05
Design
Open-label, single group, Phase 2
Record
View on ClinicalTrials.gov ↗